Takeda Pharmaceutical
316 hedge funds and large institutions have $1.97B invested in Takeda Pharmaceutical in 2021 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 107 increasing their positions, 70 reducing their positions, and 49 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 70
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 49
1% more funds holding
Funds holding: 312 → 316 (+4)
7% more call options, than puts
Call options by funds: $95.8M | Put options by funds: $89.6M
0.06% less ownership
Funds ownership: 6.9% → 6.84% (-0.06%)
0% less capital invested
Capital invested by funds: $1.98B → $1.97B (-$9.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$182M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$33.5M |
| 3 |
BlackRock
New York
|
+$24.6M |
| 4 |
GCM
Glenview Capital Management
New York
|
+$15.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Adelphi Capital
London,
United Kingdom
|
-$138M |
| 2 |
PC
Paulson & Co
New York
|
-$118M |
| 3 |
Renaissance Technologies
New York
|
-$38.6M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$15.4M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$14.1M |
TAK Hedge Fund Activity: Q1 2021 in Review
316 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2021, worth a combined $1.97B — down 0.47% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new TAK positions and 49 closed out — a net gain of 7 holders — while 107 added to existing stakes and 70 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $182M. The largest seller was Adelphi Capital, exiting entirely with an estimated $138M sold.
- 316 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2021, up from 312 in Q4 2020.
- Funds reported $1.97B of Takeda Pharmaceutical stock for Q1 2021, down 0.47% quarter-over-quarter.
- 56 funds opened new Takeda Pharmaceutical positions in Q1 2021 and 49 closed out, a net change of +7 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2021 was ARK Investment Management, an estimated $182M added.
- The largest Takeda Pharmaceutical seller in Q1 2021 was Adelphi Capital, an estimated $138M sold.
Based on aggregated 13F filings for Q1 2021.